Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2425 participants.

Also called NCT02586155

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 2,425 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02586155
Main results
  • Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial JAMA, 2020-04-28 DOI, PubMed 32219359, PMC7101505 Not in the PMC Open Access subset.
Other papers using this trial's data
  • Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial Cardiovascular diabetology, 2021-06-22 DOI, PubMed 34158057, PMC8218391 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Australia, Belgium, Bulgaria, Croatia, Germany, Hungary, Israel, Mexico, Netherlands, Poland, Russia, Serbia, Slovakia, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02586155. Randomized; triple masking; primary purpose prevention. Start 2015-11 (actual); primary completion 2020-11-30 (actual). Results posted on 2021-08-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Acronym
BETonMACE
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Apabetalone
Intervention (Drug)
Placebo
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Rosuvastatin
Lead sponsor
Resverlogix Corp (class: industry)
Collaborator
PPD Development, LP (class: industry)
Collaborator
ICON plc (class: industry)
Collaborator
Medidata Solutions (class: industry)

Record details

Record id
cardio:ct-nct02586155
Content hash
a4db6173f9f1feabc441b359fdfdffd8449ded5d4b75f67454502e8adf0779a6